<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04955379</url>
  </required_header>
  <id_info>
    <org_study_id>EYEQUE-005</org_study_id>
    <nct_id>NCT04955379</nct_id>
  </id_info>
  <brief_title>Study in Pediatric Volunteers of a Handheld Device Versus a Standard Diagnostic Device in Ophthalmic Refraction</brief_title>
  <official_title>An Exploratory Study in Healthy Pediatric Volunteers to Evaluate the Performance of a Handheld Device Compared With Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeQue Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EyeQue Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is exploratory and examines whether the refraction results obtained from a novel&#xD;
      optical device yields results similar to the ophthalmic refraction measurements obtained from&#xD;
      an autorefractor in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is exploratory and examines whether the refraction results obtained from a novel&#xD;
      optical device yields results similar to the ophthalmic refraction measurements obtained from&#xD;
      an autorefractor in the age stratum of 6 through 17 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">May 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tendency of, or achieving, statistical equivalence of refraction measurements EQ103 (non-cycloplegic) compared with autorefractor (non-cycloplegic)</measure>
    <time_frame>Day 1</time_frame>
    <description>Tendency of, or achieving, statistical equivalence of refraction measurements EQ103 (non-cycloplegic) compared with autorefractor (non-cycloplegic)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed by age-strata.</measure>
    <time_frame>Day 1 and 14</time_frame>
    <description>EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed in the following age-strata.&#xD;
Age Groups&#xD;
6 to 12 y.o. &gt;12 to &lt;18 y.o.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed by age-strata.</measure>
    <time_frame>Day 1 and 14</time_frame>
    <description>EyeQue EQ103 (non-cycloplegic) and the autorefractor (cycloplegic) assessed by refractive error measured by each device analyzed in the following age-strata.&#xD;
Age Group&#xD;
6 to 12 y.o.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ103 without cycloplegia will be compared to EQ103 with cycloplegia by younger age-strata.</measure>
    <time_frame>Day 1 and 14</time_frame>
    <description>EQ103 without cycloplegia will be compared to EQ103 with cycloplegia in the following age-strata.&#xD;
Age Group&#xD;
6 to 12 y.o.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Refractive Errors</condition>
  <condition>Accomodation</condition>
  <condition>Diagnostic Self Evaluation</condition>
  <arm_group>
    <arm_group_label>Measurements</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will be tested with the Autorefractor and the EQ103 device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EQ103</intervention_name>
    <description>Ophthalmic Refractometer with a measurement and background channel</description>
    <arm_group_label>Measurements</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Ages â‰¥6 y.o. and &lt;18 y.o.&#xD;
&#xD;
          -  Binocular vision&#xD;
&#xD;
          -  Parent(s) or Guardian(s) willing and able to give informed consent on behalf of the&#xD;
             subject.&#xD;
&#xD;
          -  Subject able to follow all study procedures and requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Spherical correction &gt; +8 or &lt; -10&#xD;
&#xD;
          -  Using anticholinergic medications (including first-generation antihistamines) or other&#xD;
             medications known to affect visual acuity within the greater of 3 days or 5 half-lives&#xD;
             prior to enrolling in this study.&#xD;
&#xD;
          -  Using an investigational drug or approved therapy for investigational use within the&#xD;
             greater of 3 days or 5 half-lives prior to enrolling in this study.&#xD;
&#xD;
          -  Has initiated any new medication in the past 2 weeks that, in the best medical&#xD;
             judgment of the investigator, would impact their participation in the study or ability&#xD;
             to use the EyeQue EQ103 device,&#xD;
&#xD;
          -  Any self/caregiver-reported mental illness or condition of the subject, including but&#xD;
             not limited to claustrophobia, fear of simulators, nyctophobia.&#xD;
&#xD;
          -  Any self/caregiver-reported neurological diseases of the subject, including but not&#xD;
             limited to: epilepsy, nystagmus.&#xD;
&#xD;
          -  Any self/caregiver-reported glaucoma diagnosis of the subject.&#xD;
&#xD;
          -  Eye disease, including but not limited to:&#xD;
&#xD;
               -  Cataracts&#xD;
&#xD;
               -  Macular degeneration&#xD;
&#xD;
               -  Eye infection (by self-report or observation)&#xD;
&#xD;
               -  Keratoconus&#xD;
&#xD;
               -  Diabetic neuropathy/retinopathy&#xD;
&#xD;
               -  Cytomegalovirus retinitis&#xD;
&#xD;
               -  Color blindness (any color deficiency)&#xD;
&#xD;
               -  Diabetic macular edema&#xD;
&#xD;
               -  Amblyopia&#xD;
&#xD;
               -  Chronic or acute uveitis&#xD;
&#xD;
               -  Strabismus&#xD;
&#xD;
               -  Astigmatism &gt; 3 diopters&#xD;
&#xD;
               -  Macular hole&#xD;
&#xD;
          -  Lack physical dexterity to properly operate the EyeQue device.&#xD;
&#xD;
          -  Lack the ability to follow instruction.&#xD;
&#xD;
          -  Lack binocular vision.&#xD;
&#xD;
          -  Are colorblind.&#xD;
&#xD;
          -  Had eye surgery within the last 12 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noam Sapiens, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noam Sapiens, PhD</last_name>
    <phone>(510) 953-6433</phone>
    <phone_ext>600</phone_ext>
    <email>noam.sapiens@eyeque.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ygal Rotenstreich</last_name>
    <phone>(408) 630-5086</phone>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2021</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Refraction</keyword>
  <keyword>Telehealth</keyword>
  <keyword>Vision</keyword>
  <keyword>Accommodation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

